Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens.
Matthew J AkiyamaLindsey RibackJacqueline D ReevesYolanda S LieLinda AgyemangBrianna L NortonJulia H ArnstenAlain H LitwinPublished in: Open forum infectious diseases (2021)
Our results demonstrate RAS prevalence among DAA-naive PWID is comparable to that in the general population. Only 2 of 150 (1.3%) in our longitudinal cohort developed treatment-emergent RASs. Concern for transmission of resistant virus may therefore be minimal.